Sign inJoin waitlistJoin the waitlist

Kimberly Strickland

Physician · Presbyterian Hospital

Credentials: · · · · · ·

History

Presbyterian Hospital
2021–Present

Thomas Jefferson University Hospital
2015–2018
Internal Medicine
Thomas Jefferson University Hospital
2012–2015
Brody Sch of Med at East Carolina Univ
2008–2012

Research

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
Clinical Cancer Research · 2018 · 121 citations
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
JCO Precision Oncology · 2021 · 43 citations
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA
American journal of cancer therapy and pharmacology · 2014 · 28 citations

Massimo Cristofanilli
3 papers
AB
Amir Behdad
2 papers
Leonidas Platanias
2 papers
William Gradishar
2 papers
Andrew Davis
1 paper · 1 as a fellow
Ashley de Padua
1 paper · 1 as a fellow
BS
Brittany Simone
1 paper · 1 as a resident
Costas Lallas
1 paper
DM
Daniel Monti
1 paper
Danielle Duffy
1 paper
Edouard Trabulsi
1 paper
Emmanuel Antonarakis
1 paper

Clinical trials

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Site PI · Recruiting
Alliance for Clinical Trials in Oncology
2025–2029
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033